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GLOSSARY 
CHF -  Congestive Heart Failure 
CKD - Chronic Kidney Disease 
CHr   - Reticulocyte haemoglobin content 
CBC - Complete blood count 
CRP  -  C reactive protein 
ESA - Erythropoiesis stimulating agents 
ESR -  Erythrocyte sedimentation rate 
ESRD -  End Stage Renal Disease 
GFR -  Glomerular Filtration Rate 
HD - Haemodialysis 
Hb  -  Hemoglobin 
HIV - Human Immunodeficiency Virus 
HCV - Hepatitis C Virus 
LVH - Left Ventricular Hypertrophy 
NKF -K/DOQI- Kidney Disease Outcomes Quality Initiative  
  of National Kidney Foundation  
NSAID-  Non steroidal anti-inflammatory drugs 
MCV  - Mean corpuscular volume 
MCH    -  Mean corpuscular hemoglobin 
MCHC -  Mean corpuscular hemoglobin concentration 
PCV  -  Packed cell volume 
PD - Peritoneal Dialysis 
RBC  -  Red blood cell 
 rHuEPO-  recombinant human erythropoietin 
RES - Reticuloendothelial system 
RDW -  Red cell distribution width 
sTfr  -  Soluble transferrin receptor 
TIBC  -  Total iron binding capacity 
WBC  -  White blood cell count 
%TSAT-  Percentage transferrin saturation 
                                                   ABSTRACT 
TITLE :  A study of Haematological profile and Serum Iron indices in non-
dialysis Chronic Kidney Disease patients    
AIM : To assess the Haematological profile and Serum Iron indices in non-dialysis 
Chronic Kidney Disease patients    
BACKGROUND AND OBJECTIVES: Anemia is a common and early 
complication of chronic kidney disease patients. One contributing factor is iron 
deficiency, which may be particularly problematic during erythropoietin therapy.  
MATERIALS AND METHODS: It is a cross-sectional study conducted in 
Department of Medicine and Nephrology, Govt Rajaji Hospital, Madurai.  A total 
of 54 patients were included in our study who satisfied the diagnostic criteria of 
CKD and patients underwent clinical and renal parameters, haematological profile 
and iron status. For comparison of the results with the general population adequate 
number of controls were taken.    
 
RESULTS: Our study results showed low level of Haemoglobin,  and packed cell 
volume with increase in  severity of chronic kidney disease. Bleeding time was 
increased in 5.6% patients and elevated ESR was present in more than half of 
patients. Anemia was universal in our population. Normocytic normochromic 
anemia was found in 70.4 % of the patients and microcytic hypochromic anemia in 
another 20.4%, and 9.2% had both type of peripheral smear picture. Applying the 
NKF-K/DOQI  guidelines for nondialysis chronic kidney disease  to our population 
it was found that nearly 38.9% of the study population did not have target serum 
ferritin of 100 ng/ml and 44.4% of study population did not have target TSAT of 
>20%. 
CONCLUSION: So it is vital to address this issue of iron deficiency in patients 
with chronic kidney disease so that necessary investigations can be undertaken to 
find the cause of iron deficiency if any. So every effort should be done to identify 
the cause of anemia in CKD patients and treat the coexistent iron deficiency 
anemia in chronic kidney disease patients. And other haematological parameters 
should be monitored to find out coexisting abnormality. 
 
   
INTRODUCTION 
 
             Chronic kidney disease (CKD) encompasses a spectrum of various 
pathophysiologic processes leading to abnormal kidney function, and a 
progressive decline in glomerular filtration rate (GFR). 
              The burden of chronic kidney disease cannot be assessed 
accurately. The approximate prevalence of CKD is 800 per million 
population, and the incidence of end stage renal disease (ESRD) is 150-
200 per million population. 
              CKD is a worldwide epidemic associated with a number of co-
morbidities and hence a disease with high mortality. 1, 2 
              Anemia of chronic disease is a complex disorder determined by 
variety of factors. Although the primary defect is decreased erythropoietin 
production from the kidney, a number of other factors may play 
contributory roles. For example iron, folate, vitamin B12 deficiency due to 
nutritional insufficiency or increased blood loss, shortened RBC survival, 
hyperparathyroidism, mild chronic inflammation and aluminium toxicity. 
Anemia in CKD worsens co-morbidities of diabetes and hypertension, 
contributing to poor outcome and high mortality. 
             Untreated chronic anemia leads to a number of physiologic 
disorders including cardiovascular complications and increased mortality 
and morbidity. According to GFR and 2006 NKF-K/DOQI guidelines, 
   
CKD has been divided into 5 stages 3, 4.  Anemia usually appears at GFR 
below 60ml/min or at stage 3. 
             Renal insufficiency is also associated with bleeding tendency 
attributed to platelet dysfunction due to abnormal platelet aggregation and 
adhesiveness5, 6. White blood cell count may be decreased in uremic 
patients and anemia correction is followed by an increase in natural killer 
cells and improvement in leukocyte phagocytic function. Early 
identification and treatment of anemia in CKD may improve 
cardiovascular morbidity and mortality.7 Early treatment of anemia in 
CKD may postpone the onset of ESRD and improve survival. 
            The identification, evaluation and optimal treatment of anemia in 
CKD essentially involve complete blood count, determination of serum 
ferritin and transferrin saturation to assess iron stores and adequacy of iron 
for erythropoeisis. 
            The National Kidney Foundation's Kidney Disease Outcome 
Quality Initiative (K/DOQI) anemia guidelines recommend that during 
erythropoiesis-stimulating agent (ESA) treatment in nondialysis CKD that 
serum ferritin and transferrin saturation (TSAT) be maintained >100 ng/ml 
and 20%, respectively 8 
   
            Treatment of anemia in CKD when indicated may involve iron 
therapy, use of erythropoietin, and correction of anemia to a target 
hemoglobin of 11- 12 gm /dl.8 
             Renal replacement therapy poses a huge economic burden to the 
family and health care delivery system. 
             This study was conducted to determine the haematological profile 
and serum iron indices of non dialysis CKD patients. 
                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
AIM AND OBJECTIVES 
AIM : 
 To assess haematological profile and serum iron indices in 
nondialysis chronic kidney disease patients. 
Objectives : 
1) To study the haematological profile and serum iron indices in non 
dialysis chronic kidney disease patients. 
2) To detect the types of anemia in patients with chronic kidney disease 
3) To study the prevalence of iron deficiency in non dialysis chronic 
kidney disease patients according to National Kidney Foundation’s Kidney 
Disease Quality Initiative (NKF-K/DOQI) Guidelines. 
 
 
 
 
 
 
 
 
 
 
   
 
REVIEW OF LITERATURE 
 
 
CHRONIC KIDNEY DISEASE 
            Chronic kidney disease (CKD) has emerged as a major public 
health problem worldwide. It is well accepted that low income countries 
are unable to afford the cost of care required to manage patients with end 
stage renal disease. 
             The term chronic renal failure applies to the process of continuing 
significant irreversible reduction in nephron number, and typically 
corresponds to CKD stages 3-5. 
            The term end-stage renal disease represents a stage of CKD where 
the accumulation of toxins, fluids, and electrolytes that are normally 
excreted by the kidneys results in uremic syndrome. This syndrome leads 
to death unless the toxins are removed by renal replacement therapy, using 
dialysis or kidney transplantation.4 
          Chronic kidney disease is divided in to five stages based on the 
estimated GFR. To be classified as stage 1 or stage 2, there must be an 
accompanying structural or functional defect (eg.proteinuria, hematuria) as 
the GFR is normal or near normal in this stages.2, 3 
 
 
   
DEFINITION OF CHRONIC KIDNEY DISEASE: 3 
             National kidney foundation has defined CKD, 
CRITERIA:  
            1. Kidney damage >3 months, either structural or functional 
abnormality with or without decreased GFR, manifested by either 
pathologic abnormalities or markers of kidney damage in blood, urine or 
imaging studies. 
           2. GFR <60 ml/min/1.73 sq m for > 3 months with or without 
kidney damage. 
CLASSIFICATION OF CHRONIC KIDNEY DISEASE3: 
STAGE                DESCRIPTION                                  GLOMERULAR FILTRATION RATE                             
                                                                                                      (ml/min/1.73 m2)     
0            With risk factor for CKD                                       >90                                            
1             Kidney damage with normal or increased GFR      ≥ 90 
2             Mild decrease in GFR                                           60 – 89 
3             Moderate decrease in GFR                                    30 – 59 
4             Severe decrease in GFR                                        15 – 29 
5              Kidney failure                                                   < 15 or on dialysis 
(Stage 0 – with risk factor for chronic kidney disease) 
CALCULATION OF GFR 2, 4 
          Recommended equation for estimation of GFR using serum 
creatinine, age, sex, and race & body weight. 
   
         Two formulas are used widely to estimate kidney function from 
serum creatinine: (1) Cockcroft-Gault and (2) four-variable MDRD 
(Modification of Diet in Renal Disease). 
Cockcroft-Gault: CrCl (mL/min) = (140 – age (years) × weight (kg) × 
[0.85 if female])/ (72 × sCr (mg/dL) 
MDRD: eGFR (mL/min per 1.73 m2) = 186.3 × PCr (e–1.154) × age (e–0.203) 
× (0.742 if female) × (1.21 if black). 
PATHOPHYSIOLOGY OF CHRONIC KIDNEY DISEASE: 
               The pathophysiology of CKD involves two broad sets of 
mechanisms of damage: 
1)  Initiating mechanisms specific to the underlying aetiology (e.g. 
Immune complex and mediators of inflammation in certain types of 
glomerulonephritis or toxin exposure in certain diseases of the renal 
tubules and interstitium) 
2)  A set of progressive mechanisms, involving hyperfiltration and 
hypertrophy of the remaining viable nephrons, that are a common 
consequence following long-term reduction of renal mass, irrespective of 
underlying aetiology. The responses to reduction in nephron number are 
mediated by vasoactive hormones, cytokines and growth factors. 
   
           Eventually these short term adaptations of hypertrophy and 
hyperfiltration become maladaptive as the increased pressure and flow 
predisposes to sclerosis and dropouts of the remaining nephrons.4 
          It is important to identify factors that increase the risk for CKD, 
even in individual with normal GFR. 
          Risk factors include: 
1) Hypertension 
2) Diabetes mellitus 
3) Auto-immune disease 
4) Older age 
5) Structural abnormalities of urinary tract. 
6) Family history of renal disease 
7) A previous episode of acute renal failure 
8) Presence of proteinuria 
9) Abnormal urinary sediment 
         The most frequent cause of CKD is diabetic nephropathy most often 
secondary to type-2 diabetes mellitus. Hypertensive nephropathy is a 
common cause of CKD in elderly. Glomerulonephritis represents third 
most common cause of CKD. The early stage of CKD, manifesting as 
albuminuria and even a minor decrements in GFR, is now recognized as a 
major risk factor for cardiovascular disease. Other causes like interstitial 
   
nephritis, HIV nephropathy, etc also form a significant proportion of cases 
leading to End Stage Renal Disease.2, 4 
HAEMATOLOGICAL ASPECTS OF CHRONIC KIDNEY 
DISEASE: 
ANEMIA: 
               Anemia is a common problem for CKD patients. The anemia of 
CKD is multifactorial in origin. (But erythropoietin deficiency is the most 
important etiologic factor). Even though traditionally considered as 
normochromic normocytic anemia due to erythropoietin deficiency other 
factors like iron deficiency contributes a major proportion and this is 
worsened in patients on dialysis. 9(Eschbach et al)                
               Anemia a multifactorial risk factor for the progression of CKD to 
end stage renal disease (ESRD) reduces the quality of life and associated 
with significant morbidity and mortality. 
               Anemia develops earlier in CKD among patients with diabetes 
mellitus and this magnitude of anemia tends to be more severe than with 
non diabetic patients 10. (Mohanram A et al) 
              Degree of anemia is a reflection of severity of disease. 
              The WHO defines anemia as a haemoglobin level less than    
13gm/dl in adult men and less than 12 gm/dl in adult women. 
   
              Absolute Hb level that defines anemia in CKD has been 
determined by National Kidney Foundation’s kidney disease outcome 
quality initiative anemia guidelines as a level of less than 13.5gm/dl for 
men and 12gm/dl for women 8. 
               In general, anemia becomes more frequent as renal function 
declines, becoming almost universal in end-stage renal disease (ESRD).    
Hsu and co-workers studied 12,055 adult ambulatory subjects from health 
clinics in Boston, found that mean Haematocrit values decreased 
progressively when creatinine clearance was below 60 mL/min in men and 
below 40 mL/min in women. Moderately severe anemia, Haematocrit less 
than 33%, was common (present in >20% of patients) only when GFR was 
severely depressed, less than 30 mL/min in women and 20 mL/min in men.  
Erythropoietin deficiency along with absolute or functional deficiency of 
iron, accounts for nearly 90% cases of anemia. India is leading in iron 
deficiency anemia in the world. With or without CKD, anemia affects an 
estimated 2/3rd population in India, as per national family health survey 11. 
(Anwer et al) 
ETIOLOGY OF ANEMIA IN CKD: 
BASIC ETIOLOGY: 
1) Erythropoietin deficiency 
2) Iron deficiency (absolute/functional) 
   
       - Decreased RBC life-span, 
       - Reduced food / iron intake & absorption due to uremia, 
       - Increased iron loss – GI bleeding, other bleeding tendency. 
       - Urinary loss of transferrin as a part of proteinuria leading to 
impaired iron transport. 
CONTRIBUTORY FACTORS: 
1) Uremic toxins 
2) Drugs 
3) Aluminium toxicity 
4) Secondary hyperparathyroidism / bone marrow fibrosis 
5) Folate / B12 deficiency 
6) HIV / HCV infections 
7) Chronic inflammation & cytokines 
8) Hemoglobinopathy 
9) Co-morbid conditions like auto-immune diseases, etc                                               
CONSEQUENCES OF ANEMIA: 2, 11  
1) Decreased quality of life 
2) Decreased exercise tolerance 
3) Decreased cognitive functions 
4) Left  ventricular hypertrophy 
5) Congestive heart failure 
   
6) Angina / myocardial infarction 
7) Disturbed sleep pattern 
8) Decreased immune response  
Impact of Anemia on Cardiac Health: 
         Cardiac disease has a grave impact on patients with kidney disease, 
reducing quality of life and increasing risk for hospitalizations and death. 
Among hemodialysis patients, mortality risk due to cardiovascular disease 
is more than 15 times greater than in the normal population. 
Approximately 50% of deaths in CKD are related to cardiovascular 
disease, owing to congestive heart failure (CHF), acute myocardial 
infarction, and sudden cardiac death.12 (Wali RK et al). Indeed, patients 
with CKD are far more likely to die of cardiac events than to progress to 
ESRD.13 (Keith DS et al). Anemia, a common complication in CKD, may 
play a key role in incrementing risk. 
          Anemia in CKD results in chronic changes in the cardiovascular 
system. Part of the body's compensation for anemia is a high cardiac 
output and vasodilated state, which partially mitigates the effect of reduced 
oxygen carriage by the bloodstream. Chronic elevation of cardiac output 
may be maladaptive, increasing cardiac work and resulting in left 
ventricular hypertrophy and increased risk for cardiovascular events 13, 14. 
 
   
ANEMIA AND LEFT VENTRICULAR HYPERTROPHY (LVH) 
        Left ventricular hypertrophy is the cardiac abnormality most often 
found in association with chronic anemia. It is readily diagnosed by 
characteristic echocardiogram findings, 14 with left ventricular mass index 
greater than 134 and 110 g/m2   in men and women, respectively.15 
(Abergel E et al) It is a particularly important finding in that it is a strong 
independent predictor of mortality risk. Each 1 gm/dL decrease in 
Hemoglobin was associated with a 6% increase in risk for LVH.16 
         Taken together, this literature indicates a fairly consistent association 
between anemia and LVH. Smaller studies with correction of severe 
anemia have demonstrated at least partial regression of LVH.  
Other Effects of Anemia in Chronic Kidney Disease: 
          Anemia and its direct consequence, reduced oxygen carriage and 
delivery, may have other detrimental effects in patients with CKD. 
Worsening anemia could potentially accelerate the progression of kidney 
disease by depriving diseased kidneys of oxygen. A post hoc analysis of 
the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II 
Antagonist Losartan) trial was reported recently by Mohanram and 
associates. Among 1513 subjects with type 2 diabetes mellitus, initial Hb 
was an important predictor of renal outcome, including time to ESRD or 
doubling of serum creatinine. The risk was increased by 11% for every       
   
1g/dL decrease in Hb concentration.  For every 1 g/dL decrease in Hb, 
there was a 30% increase in infection risk. 
         A number of studies have assessed the effects of anemia on brain and 
cognitive function. The results have consistently linked anemia to impaired 
function and rHuEPO treatment to measurable improvements. (Benz RL et 
al) 17, 18 
BENEFICIAL EFFECTS OF CORRECTION OF ANEMIA: 
1) Lesser need of blood transfusion 
     -  Lesser risk of Human Immunodeficiency Virus/Hepatitis C   Virus 
     -  Less chances of alloantibodies (transplant rejection) 
     -  Less chances of iron overload 
2) Improved quality of life & work tolerance 
3) Regression of Left ventricular hypertrophy and infrequent Congestive 
heart failure 
4) Reduced occurrences of angina / Myocardial infarction 11 (Anwer et al) 
DIAGNOSTIC EVALUATION OF ANEMIA IN CKD: 
           Because the diagnosis of erythropoietin deficiency is one of 
exclusion, the evaluation should focus on excluding other causes of anemia 
with an appropriate history, examination and laboratory testing. 
1) Haemoglobin–severity of anemia is assessed by measuring Hb% 
concentration, and haematocrit. 
   
2) Complete blood count should be reviewed for any related problems in the 
leukocyte or platelet cell lines. 
3) Red blood indices should be examined and anemia classified as 
microcytic, normocytic or Macrocytic. 
         Anemia of CKD usually results in a normocytic erythrocyte 
classification.  If microcytosis is present, then iron deficiency, thalassemia 
and myelodysplasia should be considered. With macrocytosis, folic acid 
and vitamin B12 deficiency must be excluded.     Echinocytes or burr cells 
were thought to be characteristic of chronic renal failure. However, even 
normal cells undergo a reversible transformation to burr cell-like 
echinocytes when exposed to a glass surface or incubated uremic plasma.  
4) Faecal blood testing19 (Bini EJ et al) and upper Gastrointestinal scopy 
should be performed to evaluate for occult gastrointestinal bleeding and 
motion examination for parasitic infestation should be done. 
5) Iron profile including serum ferritin and transferrin saturation, serum 
transferrin receptors should be done to rule out iron deficient state.   IRON 
DEFICIENCY IN CKD: 
         The peripheral blood picture characterised by microcytosis and 
hypochromia, manifested by decreased RBC count, MCV, MCH, MCHC 
indicating reduced Hb due to iron deficiency, the degree of which depends 
upon the extent of iron deficiency which increases as CKD progresses. 
   
DIAGNOSIS OF HYPOPROLIFERATIVE ANEMIA 4     
TESTS IRON DEFICIENCY 
ANEMIA 
INFLAMMATION RENAL DISEASE 
Anemia Mild to severe Mild Mild to severe 
MCV(fL) 60-90 80-90 90 
MORPHOLOGY Normo-microcytic Normocytic Normocytic 
SERUM IRON(µg/L) < 30 < 50 Normal 
TIBC (µg/L) > 360 <300 Normal 
SATURATION % <10 10-20 Normal 
FERRITIN(µg/L) < 15 30-200 115-150 
                                                                                                                    
 ERYTHROPOIETIN 20: 
             Erythropoietin (EPO) is a 34-kDa glycoprotein hematopoietic 
growth factor that can control the rate of red cell production by acting on 
erythroid precursors in the bone marrow production. Plasma EPO level is 
4-27 U/L. In the kidney the peritubular interstitial cells outside the tubular 
basement membrane produce EPO. In patients with renal disease, the 
reduction in EPO production is roughly proportional to the degree of 
excretory impairment. 20(Erslev AJ) 
 
 
 
   
Inflammatory cytokines in anemia21, 22: 
       Increased levels of inflammatory cytokines are detected in CKD. 
These cytokines inhibit the production of EPO and render erythroid cell 
insensitive to the action of EPO, leading to normocytic normochromic 
anemia. 21(Rogers JT et al) 
Markers of Iron Status in CKD                                                                                
           The most routinely used iron markers in patients with CKD include 
serum Iron, transferrin saturation ratio; and serum ferritin. Although the 
bone marrow iron staining is the reference standard, it is a semi 
quantitative measure and rarely is used beyond investigational purposes 23, 
24. (Kalantar-zadheh K et al). Similarly, direct liver iron store assessment 
requires the invasive procedure of liver biopsy, although the indirect 
assessment via the superconducting quantum interference device (SQUID) 
may be a promising method that currently can be accessed only in very 
few centres. 
 Other non traditional used iron markers in patients with CKD, Include:      
           1. Reticulocyte hemoglobin content (CHr), is the amount of Hb 
present in each reticulocyte. CHr less than 28 pg indicate iron deficiency. 
           2. Percentage of hypochromic red cells25 (Bovy C et al) is an 
indicator of iron deficiency as newly formed RBCs become hypochromic 
   
as a consequence of iron deficiency. Hypochromic cells more than 10 
%indicates iron deficiency. 
           3. Soluble transferrin receptor concentration ,  Because erythroid 
cells have the highest numbers of transferrin receptors of any cell in the 
body, and because transferrin receptor protein (TRP) is released by cells 
into the circulation, serum levels of TRP reflect the total erythroid marrow 
mass.  TRP levels are elevated is absolute iron deficiency. Normal values 
are 4–9 g/L determined by immunoassay. This laboratory test is becoming 
increasingly available and, along with the serum ferritin, has been 
proposed to distinguish between iron deficiency and the anemia of chronic 
inflammation 4. 
           4. Erythrocyte zinc protoporphyrin (Canaves C et al) 26 increased 
levels reflect an inadequate iron supply to erythroid precursors to support 
hemoglobin synthesis. Normal values are <30 g/dL of red cells. In iron 
deficiency, values in excess of 100 g/dL are seen. The most common 
causes of increased red cell protoporphyrin levels are absolute or relative 
iron deficiency and lead poisoning. 
ROLE OF HEPCIDIN: 
            Hepcidin, an acute phase reactant protein produced in the liver. 
Hepcidin inhibits intestinal iron absorption and iron release from 
macrophages and hepatocytes. Because hepcidin production is increased 
   
by inflammation, and high hepcidin concentrations limit iron availability 
for erythropoiesis, hepcidin likely plays a major role in the anemia of 
inflammation and rHuEPO resistance. 
             If storage iron is elevated, then the liver synthesizes hepcidin, 
which feeds back to the gastrointestinal tract and to the placenta in 
pregnant women, preventing additional exogenous iron absorption. 
Hepcidin also inhibits the release of iron from the RE system to circulating 
transferrin. 
             Hepcidin activity in normal individuals is increased in the setting 
of inflammation/infection, primarily through the release of IL-6 by Kupffer 
cells in the liver. This explains the phenomenon of Reticuloendothelial 
blockade in which storage iron is not released to circulating transferrin, 
resulting in a high serum ferritin and low TSAT level. Not surprising, there 
is a significant correlation between hepcidin and serum ferritin because 
both are acute-phase reactants. 27(kalantar- zadeh et al) 
Ferritin Synthesis: The Role of Inflammation27 
        Under normal amounts of body iron loading, most cells contain little 
ferritin, whereas cells in the reticuloendothelial system (RES) may contain 
larger amounts of ferritin. During the acute-phase response, pro-
inflammatory cytokines such as IL-1 and TNF-alpha increase the synthesis 
of ferritin. 
   
         Hypothetically, higher amounts of ferritin may trap more body iron 
and protect the individual against worsening infection, the start of which 
invariably is associated with inflammation. Hence, inflammation-induced 
hyperferritinemia may result in a so-called “functional iron deficiency,” 
which may be useful in “acute” inflammation by iron containment in the 
RES sites but harmful under “chronic” inflammation by leading to 
refractory anemia such as in CKD or other chronic disease states. 
          Hence, a low ferritin level (e.g., 200 ng/ml in hemodialysis patients 
or 100ng/ml in nondialyzed patients with CKD) is a reliable indicator of 
iron deficiency, whereas a normal to moderately high serum ferritin does 
not rule out iron deficiency or indicate adequate or too much Fe on 
board.27 
HYPERFERRITINEMIA IN CKD: 
 
           The increase in serum ferritin during inflammation, infection, liver 
disease, malignancies, and other non–iron-related conditions may hinder 
the ability to assess the iron status in CKD under the concurrent presence 
of foregoing conditions. Serum ferritin is a marker of malignancy, such as 
in neuroblastoma, renal cell carcinoma, or Hodgkin’s lymphoma. 
Hyperferritinemia also is associated with liver dysfunction, probably 
because liver is the main organ to clear circulating ferritin molecules. High 
   
ferritin levels have been reported in patients who had CKD with 
glomerular disease and proteinuria. 
           Chronic inflammation is common in patients with CKD, and up to 
40 to 70% of patients with CKD may have increased C-reactive protein 
(CRP) levels on a chronic basis. Hence, inflammation probably is the most 
common confounder in CKD-associated hyperferritinemia and may 
contribute to it more strongly than Iron. There are many other, similar 
models of hyperferritinemia in chronic disease states, including 
rheumatoid arthritis, in which Iron deficiency is present in 50% of patients 
yet serum ferritin levels are normal or increased 27. 
           In patients with CKD, hyperferritinemia is paradoxically associated 
with Erythropoiesis stimulating agents hypo responsiveness and a more 
severe anemia. A significant association between serum CRP and ferritin 
that was independent of age, gender, race, and diabetes was found. 
Multivariate models showed that both CRP and TSAT, independent of 
each other, correlated significantly with serum ferritin. These findings 
suggest that a moderately high serum ferritin is not just a mere marker of 
Fe stores but more an indicator of inflammation and/or malnutrition as 
well as other non–iron related conditions in patients with CKD .27 
 
 
   
SERUM FERRITIN AND MORTALITY IN CKD: 
           Hyperferritinemia-associated morbidity might be due to non–Iron-
related factors. Because serum ferritin is a positive acute-phase reactant, 
hyperferritinemia associated increased risk for infection and death may be 
a mere epiphenomenon. Therefore, considering high ferritin levels as the 
primary cause of increased mortality in the setting of inflammation or 
infection and preventing optimal anemia management with intravenous 
Iron for serum ferritin levels 500 or 800 ng/ml may be irrational.27 
IRON MONITORING 2, 8 
           The K/DOQI anemia guidelines recommend that during the 
initiation of rHuEPO treatment, iron status be tested every month in 
patients not receiving ongoing iron repletion. Once rHuEPO dosing and 
iron maintenance have stabilized, the guidelines recommend monitoring at 
least every 3 months. 
            Serum ferritin is an indirect measure of storage iron29. The 
diagnostic value of serum ferritin, however, is limited by its behaviour as a 
potent acute-phase reactant.  Clinical settings may arise in which ferritin 
values may be quite high even in the presence of iron deficiency, such as 
in hemodialysis patients, in whom the test probably has a sensitivity of 
only 41% to 54%. Because of the extraordinarily high rate of false negative 
   
results, iron deficiency in hemodialysis patients cannot be excluded by 
serum ferritin more than 100ng/ml. 
        Percent transferrin saturation (TSAT) assesses the availability of 
circulating iron, calculated as TSAT = (serum iron/total iron-binding 
capacity) × 100. K/DOQI guidelines recommend using a value of less than 
20% as an indicator of iron deficiency in patients with kidney disease. 
        Percentage of hypochromic red cells has been found to be a useful 
measure of iron status in CKD patients. The test has one important 
limitation: it is affected by changes in erythrocyte mean corpuscular 
volume (MCV). When samples are stored or shipped, the MCV may be 
significantly altered. 
        Reticulocyte hemoglobin content (CHr) is a direct measure of iron 
status at the level of the reticulocyte. Because it is a measure of content 
instead of concentration, it is unaffected by changes in cell volume. In 
addition, because reticulocytes circulate for only approximately 24 hours, 
test results can indicate very acute changes in iron status .Generally, a CHr 
value of less than 29 to 31pg indicates a need for more intensive iron 
treatment.  
         Hsu et al. 30 studied iron status in CKD in the NHANES III survey 
(1988 to 1994) and found iron indices suggestive of iron deficiency to be 
present and to contribute to anemia in many subjects.  
   
         Typical markers of iron deficiency used in CKD are serum ferritin 
<100 ng/ml and TSAT < 20%. Clinicians often use these thresholds to base 
iron treatment decisions, and K/DOQI guidelines recommend these levels 
in nondialysis CKD. Specifically, the K/DOQI guidelines indicate that if 
either value is low then iron treatment is recommended.                 
            Steven Fishbane et al 31 primary finding is that between 57.8 and 
72.8% of subjects with CKD have either serum ferritin < 100 ng/ml or 
TSAT < 20%. In contrast to these relatively high values of serum ferritin 
(100 ng/ml) and TSAT (20%) that indicate insufficient iron in CKD, in the 
general population lower thresholds of serum ferritin (15 to 30 ng/ml) and 
TSAT (15%) are often used. The great prevalence of low iron indices 
found may not indicate iron deficiency per se, but rather impaired iron 
delivery concurrent with inflammation, a complex syndrome that occurs 
with progressive CKD. However, it is plausible that iron deficiency might 
be more common than expected because in CKD the prevalence of 
gastrointestinal pathology with blood loss is probably increased, sampling 
of blood for laboratory testing is common, and hospitalizations and surgery 
for other intercurrent illness could contribute to blood loss. In addition, 
many patients are treated with Erythropoiesis stimulating agents, further 
depleting iron stores. 
   
           Gotloib et al. 32 these investigators performed sternal bone marrow 
biopsies on 47 patients with CKD and Hb < 12 g/dl. Remarkably, severe 
iron deficiency was found in 46 of 47 subjects. Patients were subsequently 
treated with intravenous iron, with most responding with improved Hb 
concentration 32, indicating that iron deficiency is a common problem 
among patients with nondialysis CKD.  
 
Evaluation of Iron Storage-Serum Ferritin  
         The most recent K/DOQI guidelines recently have recommended that 
serum ferritin should be maintained greater than 200ng/mL for 
haemodialysis’ patients. For patients with CKD not yet on dialysis or those 
on peritoneal dialysis, The K/DOQI guidelines recommend maintaining 
serum ferritin greater than 100ng/mL in these populations. 
 
Evaluation of Iron Availability—Transferrin Saturation and 
Reticulocyte Hemoglobin Content (CHr)  
         The K/DOQI recommended level of transferrin saturation is 20%, for 
all populations with CKD. The K/DOQI recommendation for reticulocyte 
haemoglobin (CHr) content is 29pg. 
 
 
   
Anemia treatment algorithm 
 
 
Hb testing in all patients with CKD at least annually 
           
     
Hb < 13.5 g/dl, adult males, or Hb < 12 g/dl, adult females 
   
 
 
Diagnosis of anemia 
  
 
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− 
 
 CBC + RBC indices to assess anemia    TSAT, ferritin, or CHr 
severity, adequacy of nutrients such as 
Vitamin B12, folate, iron 
 
Absolute reticulocyte count (corrected 
for Hb value) to assess erythropoietic         HD                       PD or nondialysis CKD 
activity                  ferritin < 200 ng/ml            ferritin < 100 ng/ml 
     And                             and 
                             TSAT < 20% or                       TSAT < 20%  
__________________________               CHr < 29 pg/cell 
             
Normochromic,   Macrocytic      Microcytic     
Normocytic          Vitamin B12   Iron deficiency 
CKD              and/or folate        aluminium 
              Deficiency          overload 
 
Start/adjust ESA     Start  
based on Hb         multivitamin    parenteral iron             Oral iron or IV iron, if      
                                                                                               necessary 
   
TREATMENT OF ANEMIA: 8, 2 
1. Dialysis   
            Dialysis per se typically has little effect with regard to correcting 
the anemia, although a mild increase in hemoglobin concentration may 
result from the decrease in bleeding tendency.  
2. Iron and Folate Supplementation 
The goals of iron therapy are:   
              To achieve and maintain a target range Hb level, 
              To avoid depletion of storage iron,  
              To prevent iron deficient erythropoiesis,  
              To minimise the dose of ESA  
3. Transfusion Therapy 
         Transfusions with packed red cells are necessary to counteract the 
effects of acute blood loss. Transfusions occasionally are needed to 
maintain acceptable hemoglobin concentrations in patients who do not 
respond adequately to EPO. 
4. Recombinant Erythropoietin Administration: 
    Currently available Erythropoiesis stimulating agents are11  
      1. Short acting: Epoietin alpha, Epoietin beta 
      2. Long acting: Darbepoietin alpha 
   
      3. Newer erythropoiesis stimulation therapies: Continuous 
erythropoietin receptor activator (C.E.R.A), peptide based ESA hematide, 
Synthetic eryhropoiesis protein (SEP), EPO gene therapy.  
           The National Kidney Foundation has published detailed guidelines 
for EPO administration to patients with the anemia of chronic renal 
diseases. In short, the presence of an anemia with hematocrit of less than 
33 percent or hemoglobin of less than 11 gm/dl should initiate a thorough 
search for conditions unrelated to decreased EPO production or action. 
Measurements of folic acid and B12 levels should be carried out, with 
special attention to iron, iron-binding capacity, and ferritin levels. 
Determination of EPO levels is not necessary. 
          The National Kidney Foundation recommended an increase in the 
target hematocrit to 33 to 36 percent and target hemoglobin to 11 to 
12gm/dl.  To achieve the target hematocrit within 3 to 4 months of therapy, 
the initial EPO dose in adult patients should be 80 to 120 units/kg/week 
divided into two or three subcutaneous injections or 120 to 
180units/kg/week given as three intravenous injections. The response 
should be monitored by measuring hematocrit and haemoglobin at least 
once every 2 weeks. Once the target hematocrit is reached, most adult 
patients can be maintained by a total EPO administration of approximately 
50to100units/kg/week.   
   
         Adequate iron supplies must be maintained for erythropoiesis. A 
diagnosis of absolute or functional iron deficiency should be made before 
patients are supplemented with IV iron. The most widely used criteria 
include a ferritin level less than 100 ng/ml and/or transferrin saturation less 
than 20 percent. 29 (Jaime Caro et al) 
         The most widely used IV iron preparations are iron-dextran, iron-
sucrose, and iron-gluconate. Iron-dextran and iron-sucrose can induce 
anaphylactic reactions; iron-gluconate can induce hypotension. 
Causes of erythropoietin resistance:  
Common causes:  
      The most common causes of a poor response are 
                       Inadequate iron supply,   
                       Persistent iron deficiency, 
                       Hospitalisation for infection, 
                       Temporary and permanent catheter insertion, 
                        Hypoalbuminemia,  
                        Elevated CRP level.  
          Aluminium toxicity may be responsible for resistance to treatment 
and should be suspected in patients with microcytic red cell indices. 
Uncommon causes: pancytopenia, aplastic anemia, haemolytic anemia, 
chronic blood loss, inflammatory diseases, infection, ACE inhibitors.11 
   
Adverse Effects of Erythropoietin  
         Hypertension- most common complication 
         Seizures, 
         Thrombosis of arteriovenous fistulas,  
         High potassium levels 
         Hyperphosphatemia.  
         Pure red cell aplasia (PRCA). Patients with PRCA present with a low 
absolute reticulocyte count and resistance to EPO treatment. Marrow 
examinations have shown a decrease in erythroid precursors. 
        Adjuvant to erythropoietin, Erythropoiesis stimulating agents 
(ESA) or iron therapy: 11 the aim of add on therapy are to enhance 
responsiveness to ESA hypo responsive patients and to decrease cost by 
decreasing ESA doses ;  L-carnitine, vitamin E, androgens, statins , 
vitamin C. However KF-K/DOQI found inefficient evidence to 
recommends use of adjuvant in management of anemia in patients with 
CKD. 
        Amelioration of the anemia has resulted in a variety of beneficial 
effects and in general has dramatically improved the quality of life of 
uremic patients. 
 
   
DISORDERS OF HEMOSTASIS IN CHRONIC KIDNEY 
DISEASE2, 4, 28, 29 
         Excessive bleeding has long been recognized as an important 
complication of the uremic state. That includes epistaxis, gastrointestinal 
haemorrhage, excessive bleeding with tooth brushing, or easy bruisability. 
More severe bleeding episodes tend to occur with trauma or after invasive 
procedures, such as renal biopsy, rather than spontaneously. 
Hemopericardium and subcapsular hematoma of liver occur but less 
frequently than other bleeding manifestations. 
        It has long been noted that bleeding in uremic patients occurs despite 
normal or elevated circulating levels of coagulation factors. Whereas the 
number of circulating platelets is generally normal, the function of 
platelets is often impaired. 6 (Escolar et al) 
         Other coagulation parameters (partial thromboplastin time, 
prothrombin time, and fibrinogen) are not altered in uremia.  
         Evidence for platelet dysfunction includes elevated bleeding time, 
diminished in vitro response to adenosine diphosphate and epinephrine, 
and reduced ristocetin-induced platelet agglutination.5 (Fegurson HJ et al) 
        The most consistent abnormality in platelet function in uremia is 
impaired interaction of platelets with the vascular sub endothelium. As a 
result, platelet adhesion and aggregation are hindered. The best measure of 
   
platelet- vessel wall interaction is the bleeding time, a simple method 
tested by making small incision of the skin and measuring the time from 
first drop of blood to the last oozing of blood from the cut. 
        The platelet functional abnormalities are: 
• Abnormal aggregation to ADP, adrenaline, collagen 
• Decreased platelet adhesiveness  
• Reduced platelet factor 3 availability 
• Acquired storage pool defect 
• Abnormal prostaglandin metabolism 
• Increased prostacyclin 
• Defective platelet cyclooxygenase 
          Platelet receptors that play a critical role in adhesion to the vessel 
wall and aggregation, GP1b and GPIIb-IIIa, are probably not significantly 
reduced in quantity in uremia. However, interaction of these receptors with 
vessel wall proteins may be abnormal. In particular, activation of GPIIb-
IIIa to facilitate its adhesion to vWF may be impaired. Finally, the platelet 
cytoskeleton may be altered, with diminished actin incorporation and 
suboptimal intracellular trafficking of molecules.2 
ROLE OF ANEMIA IN PLATELET DYSFUNCTION: 
           Anemia is an important contributor to uremic platelet dysfunction. 
During normal circulation, erythrocytes tend to force the flow of platelets 
   
radially, away from the centre of flow and toward the endothelial surfaces. 
When vascular injury occurs, platelets are in closer opposition to the vessel 
wall, facilitating platelet adherence and activation by vessel wall 
constituents such as collagen. With anemia, more platelets circulate in the 
centre of the vessel, further from endothelial surfaces, hindering efficient 
platelet activation. In addition, anemia may contribute to platelet 
dysfunction because adenosine diphosphate release by erythrocytes 
normally stimulates platelet interaction with collagen.2 
THERAPY FOR BLEEDING IN UREMIC PATIENTS: 2  
1. Dialysis:  
          Dialysis reduces uremic platelet dysfunction and the risk for 
bleeding. 
2. Correction of anemia:  
          Treatment of anemia may help reverse platelet dysfunction, as both 
transfusion of blood and rHuEPO therapy have been found to be beneficial. 
3. Cryoprecipitate and Desmopressin: 
        Desmopressin (DDAVP) is often used to treat uremic bleeding. 
        Other treatments for uremic bleeding include infusion of 
cryoprecipitate, a plasma product rich in vWF and fibrinogen. Estrogens 
also improve platelet function by action of inhibition of vascular nitric 
oxide production. 
   
LEUKOCYTES IN CKD:  29 
           The total and differential leukocyte count and the platelet count 
usually are normal, but, as with all other hematologic parameters, the 
underlying disorder plays a modifying role. Uremia and dialysis may have 
an effect on leukocytes and platelets. The phagocytic activity of 
granulocytes may be reduced, and complement activation by the 
hemodialysis membrane may cause pulmonary leukostasis with temporary 
granulocytopenia. Cell-mediated immunity is depressed, resulting in an 
increased incidence of infections but also prolonged graft survival. 
Granulocytes show decreased migration and abnormal chemotactic 
activity.29 (Jaime Caro et al) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
                        MATERIALS AND METHODS 
Materials: 
         This study was conducted at Government Rajaji Hospital during the 
period of April 2011 to October 2011.  Fifty four non dialysis chronic 
kidney disease patients undergoing conservative management in 
medicine/nephrology units were enrolled into the study. The study subjects 
were newly diagnosed chronic kidney disease patients of either sex. 
Healthy adult individuals were recruited as controls. To ensure 
homogeneity between the control and CKD population, healthy individuals 
were selected from the friends and relatives accompanying the CKD 
patients.          
         Haematological profile was done in Pathology Department and renal 
parameters, Serum Iron indices in subjects and controls were done at the 
Department of Biochemistry, Madurai Medical College.  
The study was approved by the Ethical committee, Government 
Rajaji Hospital. An informed consent was obtained from all study 
participants. 
         Design: cross-sectional study 
         General physical examination, urinalysis and blood sugar, and 
creatinine estimation were done to establish the healthy nature of controls. 
A total of 54 patients and 20 controls were studied. 
   
Period of study :    April 2011 to October 2011. 
Diagnostic criteria: 
1. Bilateral contracted kidneys 
2. GFR <60 mL/min/1.73m2. 
Exclusion criteria: 
         Conditions that may alter the iron profile and RBC morphology were 
excluded on the basis of detailed history and clinical examination and 
basic investigations. 
         They include: 
1. Age less than 18 years  
2. Evidence of acute infection or trauma in the last four weeks  
3.  History of parenteral iron injection in the last 14 days 
4.  History of blood transfusion in the last one month 
5.  Hemoglobinopathies 
6.  Malignancy 
7.  Recent overt blood loss 
8.  On dialysis, Post-transplant status 
9.  Chronic infections like tuberculosis 
10.  Bleeding disorders, Previously diagnosed anemia and treated 
11.  Nephrotic syndrome 
12.  Chronic liver disease 
   
13.  HIV infection 
14.  Malabsorption 
15.  Steroid therapy 
16.  Patients receiving EPO therapy. 
Methods: 
Clinical examination included: 
1. Weight, height, vital parameters 
2. Major systems examination 
Haematological investigations: 
        Haemoglobin, Red blood cell count, White blood cell count, 
Haematocrit, Differential count, MCV, MCH, MCHC, Platelet count, 
RDW, Peripheral smear,  Bleeding time Clotting time, ESR, Serum 
ferritin, Total iron binding capacity, Serum iron  were done. 
      Automated hemogram was done. 
      Peripheral smear was done. ESR was measured by Wintrobes method.  
Biochemical investigations: 
      Blood sugar, renal parameters (blood urea, serum creatinine), serum 
electrolytes, Urine spot protein creatinine ratio. 
Serum ferritin: The serum ferritin was determined by enzyme linked 
immunosorbent assay. Iron level was determined by Ferrozine method 
   
without deproteinization. Total iron binding capacity (TIBC) was 
determined by Spectrophotometric Assay. 
Transferrin saturation calculated by using formula (TSAT);  
              TSAT = (serum iron/total iron-binding capacity) × 100. 
Ethical committee approval:  Obtained 
Consent    :  Informed consent was obtained 
Financial support   : Nil 
Conflict of interest  : Nil 
 
Statistical Tools   
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and   'p'   values were calculated. Kruskul Wallis chi-
square test was used to test the significance of difference between 
quantitative variables and Yate’s chi square test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship. 
   
 
   
 
 
RESULTS AND ANALYSIS OF OBSERVED DATA 
 
Table 1: Age distribution 
 
Age group 
Study cases 
(CKD) 
Control Cases 
( Normal) 
No % No % 
<20 years 2 3.7 1 5 
21-30 years 8 14.8 3 15 
31-40 years 12 22.2 6 30 
41-50 years 15 27.8 5 25 
50-60 years 17 31.5 5 25 
Total 54 100 20 100 
Range 19-60 20-58 
Mean 43.3 40.7 
SD 11.8 11.6 
 
 The study group had an age of 43.3 +11.8 years and the control 
group an age of 40.7 +11.6 years. 
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Table 2: Sex distribution 
Sex Study cases Control Cases 
No % No % 
Male 42 77.8 15 75 
Female 12 22.2 5 25 
Total 54 100 20 100 
 
 In this study out of 54 cases 42 are males and 12 are females. Males 
are 77.8% and females are 22.2%.  
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Table 3: Duration of illness 
Parameter Duration of CKD 
in months 
Range 3-24 
Mean 8.57 
SD 4.2 
 
Mean duration of illness ranged from 3 months to 24 months with an 
average of 8.57 months. 
 
 
 
 
 
 
 
   
 
 
Table 4: Glomerular filtration Rate (GFR)/ CKD stages 
CKD stages/GFR 
(ml/min/m2) 
Cases 
No % 
Stage 5   (< 15) 23 42.6 
Stage 4  (15 -29) 19 35.2 
Stage 3  ( 30-59) 12 22.2 
Stage 2   (60-89)  - - 
Stage 1   (≥ 90) - - 
Total 54 100 
Range 2.1 – 47.8 
Mean 18.77 
SD 12.01 
 
 Among 54 CKD cases, Glomerular Filtration Rate (GFR) ranged 
from 2.1 to 47.8 ml/min/m2. The mean GFR was 18.77 ml/min/m2 and SD 
12.01. There were no cases of stage 1 and 2 in the selected cases. 
 
 
 
   
 
 
 
 
 
 
CKD STAGES
22.2%
35.2%
42.6%
Stage 5   Stage 4  Stage 3  
 
 
 
 
 
 
 
 
   
 
Table 5: Risk factors for CKD 
Risk factor No. of cases 
Present Absent 
No % No % 
Diabetes mellitus 11 20.4 43 79.6 
Hypertension 27 50 27 50 
 
 Hypertension was present in 50% and Diabetes Mellitus in 20.4% of 
study cases. 
 
Table 6: Other risk factors for Anemia: 
Other risk factors for anemia No of cases 
History of bleeding manifestation 2 
Motion ova & cyst present 2 
Motion for occult blood 1 
 
 History of bleeding manifestation (gum bleeding, ecchymosis) was 
present in 2 cases, motion ova & cyst present in 2 cases and motion for 
occult blood was positive in one case. 
 
   
 
Table 7: Haematological profile between study and control group 
 
Variable 
Study group Control group ‘p’ 
Mean SD Mean SD 
Hb (gm/dl) 8.01 1.78 13.34 0.85 0.0001 
Significant 
RBC count  
(million/cumm)
3.18 0.7 4.58 0.45 0.0001 
Significant 
PCV % 
 
25.58 4.36 40.37 3.18 0.0001 
Significant 
Platelet count 
( lakhs/cumm) 
3.33 0.69 2.94 0.77 0.0517 
Not Significant 
MCV (fL) 80.83 14.12 83.82 4.03 0.7104 
Not significant 
MCH (pg) 26.15 5.12 28.72 1.64 0.0775 
Not significant 
MCHC (g/dl) 31.38 4.06 33.0 1.01 0.2786 
Not significant 
RDW% 15.92 4.33 13.93 0.63 0.1902 
Not significant 
ESR (mm/hr) 26.81 16.5 15.65 3.08 0.0056 
Significant 
 
When analyzing above data between study and control group, there 
were statistically significant differences seen in Hemoglobin (Hb), RBC 
   
count, PCV and ESR (p<0.005). Hb, RBC count PCV were low and ESR 
was high compared to control. 
 
Mean Hemoglobin was 8.01gm/dl and mean haemoglobin in males 
was 8.03 gm/dl and in females mean haemoglobin 7.71 gm/dl. Mean RBC 
count was 3.18 million/mm3, mean PCV 25.58%. Mean Red cell 
Distribution Width were15.92%. Erythrocyte Sedimentation Rate was 
elevated in 35 cases (64.8%). 
 Hemoglobin and Packed Cell Volume was low in all cases. 
 
         7 cases had neutrophilic leukocytosis and 3 cases had lymphocytosis. 
6 patients had eosinophilia.  No patient had features of lymphoma, 
leukaemia. 7 patients had thrombocytosis. 
        
 
 
 
 
 
 
 
 
   
Table 8: Association between CKD stages and other quantitative 
Haematological parameters 
Parameter Values (Mean +SD) in cases with ‘p’ 
CKD 3 CKD4 CKD5 
Hb(gm/dl) 9.23 +1.36 8.32 +1.7 7.0 +1.54 0.0002 
Significant 
RBC  
(million/cumm) 
3.45 +0.53 3.22 +0.72 3.01 +0.73 0.0892 
Not significant 
PCV % 27.88 +3.82 26.61 +4.29 23.52 +3.89 0.0059 
Significant 
MCV (fL) 81.5 +8.9 82.4 +9.3 81 +11.8 0.9704 
Not significant 
MCH (pg) 27.4 +5 25.7 +5.7 25.9 +4.8 0.5124 
Not significant 
MCHC (g/dL) 30.2 +3.4 31.2 +4.5 32.1 +4.0 0.3517 
Not significant 
RDW % 16.1 +4.6 16.5 +5.5 15.3 +3.1 0.7476 
Not significant 
Duration 
(in months) 
6.25 +3.28 8.47 +3.92 9.87 +4.44 0.0264 
Significant 
 
 There were statistically significant associations between Hb%            
(p= 0.0002), PCV (p<0.005) and duration of illness and CKD stages.       
(p< 0.05 ). As the CKD stage increases, the level of hemoglobin, packed 
cell volume decreases. These relationships have got statistical significance. 
 
   
 
 
 
Table 9: Bleeding time and clotting time 
 
Parameter Bleeding time 
in minutes 
Clotting time 
in minutes 
No % No % 
Normal 51 94.4 54 100 
Increased 3 5.6 - - 
Total 54 100 54 100 
 
Bleeding time increased in 3 patients (5.6%). Clotting time was 
normal in all patients.  
 
 
 
 
 
 
 
   
 
 
Table 10:  Peripheral smear 
 
Peripheral smear 
Study cases Control 
Cases 
No % No % 
Normocytic normochromic anemia  38 70.4 - - 
Microcytic hypochromic anaemia  11 20.4 - - 
Both types present  5 9.2 1 5 
Normal - - 19 95 
Total 54 100 20 100 
‘p’ 0.0001 
Significant 
 
 All the patients in the study cases had anaemia whereas only 5% in 
the control group had it. This difference was statistically significant                 
(p = 0.0001). When analyzing above data 38 patients (70.4%) had 
normocytic normochromic anemia, 11patients (20.4%) had microcytic 
hypochromic anemia and 5 patients (9.2%) had both type of morphology in 
peripheral smear picture.  
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Table 11: Relationship between type of Peripheral smear and serum 
Ferritin (µg/l); 
 Transferrin saturation %( TSAT) 
Peripheral Smear 
Type 
No of cases Mean TSAT Mean 
FERRITIN 
Normocytic 
normochromic 
38 32.46 381.98 
Microcytic 
hypochromic 
11 12.61 26.58 
Both 5 14.26 43.82 
 
      There was a statistically significant relationship between peripheral 
smear type and TSAT (p=<0.001) and also significant relationship between 
peripheral smear type and ferritin (p=<0.002). Serum ferritin level and 
transferrin saturation was low in patients with microcytic hypochromic 
anemia. 
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Table 12: Hemoglobin and Left ventricular hypertrophy (LVH) 
LVH No of cases Mean Hb(gm/dl)            SD    
Present 22 6.54                          1.57 
Absent 32 8.93                          1.15 
 
     Left ventricular hypertrophy was present in 40.7% of CKD cases 
(22cases). There was statistically significant relationship between 
Hemoglobin level and LVH. (P<0.001) 
 
 
 
 
 
 
 
 
 
   
Table 13: Serum Iron indices 
Serum Iron 
Indices 
Study group Control 
group 
‘p’ 
Mean SD Mean SD 
Iron (µg/l) 68.7 31.9 82.7 25.4 0.0182 
Significant 
TIBC(µg/l) 287.4 77.7 300.2 45.5 0.7936 
Not significant 
TSAT % 26.74 16.5 28.8 10.09 0.2896 
Not significant 
Ferritin(µg/l) 278.3 340.4 109.4 62.0 0.0479 
Significant 
 
 Among the serum iron indices between study and control cases, Iron 
and Ferritin values were significantly different, (p <0.05). TIBC, TSAT 
values were not significantly different.  
SERUM IRON INDICES 
 
 
 
 
 
 
 
   
 
 
 
 
Table 14: Serum iron indices and CKD stage 
 
 
CKD stage 
Value ( Mean +SD) of 
Iron(µg/l) TIBC(µg/l) TSAT% Ferritin(µg/l)
3 70.7 +32.8 269.9 +76.2 31.6 +23.5 357.9 +519.8 
4 69.3 +39.4 300.3 +77 25.3 +16.7 254.8 +254.5 
5 67.2 +25.2 286 +80.5 25.4 +11.6 256.1 +294.4 
‘p’ 0.7939  
Not 
significant 
0.4799 
Not 
significant 
0.7688 
Not 
significant 
0.9591 
Not 
significant 
  
      Serum iron indices and severity of CKD did not have statistically 
significant relationship with serum iron profile. 
 
 
 
 
 
 
   
Table 15: %TSAT and CKD Stage 
CKD STAGE TSAT % 
< 20%           > 20% Mean SD 
No % No % 
3 (12) 6 50 6 50 31.6 23.5 
4 (19) 9 47.4 10 52.6 25.3 16.7 
5 (23) 9 39.1 14 60.9 25.4 11.6 
Total (54) 24 44.4 30 55.6 26.7 16.5 
‘p’ 0.7688 Not significant 
 
Prevalence of Transferrin saturation (TSAT) < 20% is 44.4% of 
study cases. No significant relation between CKD stage and Transferrin 
saturation.  Transferrin saturation (TSAT) >20% was present in 55.6% 
cases. 
     
%TSAT and CKD 
44%
56%
 < 20%  > 20%
 
 
 
   
         
 
                 Table 16:  Ferritin (µg/L) and CKD Stage 
 
 
CKD STAGE 
Ferritin 
< 100microg/L     > 100microg/L Mean SD 
No % No % 
3 (12) 5 41.7 7 58.3 357.9 519.8 
4 (19) 9 47.4 10 52.6 254.8 254.5 
5 (23) 7 30.4 16 69.6 256.1 294.4 
Total (54) 21 38.9 33 61.1 278.3 340.4 
‘p’ 0.9591 
Not significant 
  
      Prevalence of Serum ferritin level <100 micro gm/L is 38.9% of the 
study cases. No significant relation between CKD stage and serum ferritin. 
Serum ferritin level > 100 micro gm/L was present in 61.1% cases. 
9 cases (16.67%) had serum ferritin >500 micro gm/l. 
   
 
 
 
 
 
 
Ferritin (µg/L) and CKD 
38.9%
61.1%
 < 100 µg/l  > 100 µg/l
 
 
 
 
 
 
 
   
DISCUSSION 
        Chronic kidney disease is a major public health  problem and major 
cause of morbidity and mortality worldwide. The actual prevalence of the 
initial stages of CKD is much more than the late stages. 
         However in clinical practice prevalence of stage 4 and 5 appears to 
be more because initial stages are asymptomatic and people present 
themselves when severity of symptoms increases.  
         Anemia of chronic kidney disease is multifactorial in origin. The 
renal community has long recognized that anemia can impair the quality of 
life of patients and lead to irreversible cardiac consequences33, 34. (Levy AS 
et al) 
         Anemia, an easily reversible feature of end-stage renal disease, is an 
independent risk factor for cardiac disease, as well as mortality in end 
stage renal disease patients 33, 34. 
           Available evidence demonstrates that: Both iron and erythropoietin 
are needed to produce red blood cells; as a result, unless adequate iron is 
available, Erythropoietin will be relatively ineffective. Although no tests 
are perfect indicators of the adequacy of iron stores, the TSAT and serum 
ferritin are the best measures of the body’s iron status that we currently 
have35, 36, 37. Given the prevalence of iron deficiency in CKD patients, and 
the sensitivity and specificity of TSAT and serum ferritin in detection of 
   
iron deficiency, the likelihood of iron deficiency is sufficiently high when 
TSAT is <20% and the serum ferritin is <100 ng/mL. Therefore, the TSAT 
and serum ferritin should be maintained at a level of >20% and >100 
ng/mL, respectively, in all non dialysis chronic kidney disease patients. 
         This study was undertaken with the aim to study the haematological 
profile and identifying the prevalence of iron deficiency anemia (according 
to NKF- K/DOQI Guidelines) in non dialysis chronic kidney disease 
patients.  
          Among the 54 patients selected for the study the sex distribution was 
42 male and 12 females and the mean age of the study group was 43.3yrs. 
In assessing the risk factors of chronic kidney disease in our patients, 
diabetes were prevalent in 20.4% meanwhile 50% of them had 
hypertension.  Afshar et al38 in their study found 49.1% patients were 
diabetic and 28.3% were hypertensive among CKD patients. 
           In our study mean duration of illness was 8.57 months. Applying 
the NKF staging of CKD, most of our patients came under stage 3, 4 or 5 
who were awaiting some form of renal replacement therapy as the last 
treatment option. Mean Glomerular Filtration Rate was 18.77 ml/min/m2. 
          At the time of presentation in our study, about 40.7% had left 
ventricular hypertrophy as per ECG criteria. Anemia and hypertension are 
the most important causes of left ventricular hypertrophy in chronic kidney 
   
disease patients. Hypertension and left ventricular hypertrophy are the 
major risk factors for cardiovascular death in patients with CKD.  
The relationship between anemia and cardiac disease in CKD was 
studied by Levin and co-workers, 16, 33 in their study Echocardiograms were 
performed in 175 patients attending a renal insufficiency clinic. LVH was 
found to be present in 38.9% of patients. The prevalence of LVH 
progressively increased with declining levels of renal function; 26.7% of 
patients with creatinine clearance (CrCl) greater than 50 mL/min, 30.8% 
with CrCl of 25 to 49 mL/min, and 45.2% with CrCl less than 25 mL/min. 
Each 1 g/dL decrease in Hb was associated with a 6% increase in risk for 
LVH. Furthermore, these investigators performed two echocardiograms 1 
year apart on 246 patients with early stages of CKD to determine factors 
responsible for subsequent worsening of LVH. Worsening anemia proved 
to be an important predictor, with Hb decreasing 0.85 g/dL in patients with 
ventricular growth compared with a decrease of 0.11 g/dL among patients 
with stable LVH.  
          Among study and control group there was a statistically significant 
difference present between Hemoglobin, Red Blood Cell count, Packed 
Cell Volume, and Erythrocyte Sedimentation Rate.   
         Anemia was universal in our study and it showed direct linear 
relationship with reduction in the GFR. The mean Hemoglobin in our 
   
patients was 8.01 gm/dl. There was a significant reduction in Packed Cell 
Volume with progressive increase in stage of Chronic Kidney Disease.  
Afshar et al38 and Khanam et al39 also found same linear relationship 
between Hb and GFR.  Khanam et al39 also found reduction in PCV with 
decreasing GFR.   Ijoma et al47 found mean haemoglobin 10.57 gm/dl in 
stage 3, 8.84 gm/dl in stage 4, 7.33 gm/dl in stage 5 chronic kidney 
disease. This states that anemia is very well correlated with severity of 
chronic kidney disease 
         The lower GFR or EPO production, greater loss of haematopoietic 
elements and inflammation can lead to lower haemoglobin and hematocrit 
level in CKD patients. As anorexia, nausea, vomiting are the common 
features of CKD patients, less dietary intake of nutrients needed for 
erythropoiesis might also be a factor for anemia.  In developing countries 
like India, parasitic infestation, low socioeconomic status may play a role 
in nutritional deficiency and anemia.  More over CKD patients are on 
protein restricted diet which might also have some role for occurrence of 
anemia in these patients.39 
       Peripheral smear was done in our patients with the aim to classify the 
type of anemia. As the conventionally taught normocytic normochromic 
anemia was found in 70.4 % of the patients and microcytic hypochromic 
anemia in another 20.4%, and 9.2% had both type of morphology in 
   
peripheral smear picture. Afsar et al 38also found normocytic nomochromic 
anemia in 80% patients and microcytic hypochromic anemia in 15% 
patients.  Talwar et al40 found 60% patients with microcytic hypochromic 
anemia, 30% patients normocytic normochromic anemia in their study.  
           MCV, MCH, MCHC of the patients with normocytic normochromic 
anemia were normal and low in hypochromic microcytic anemia. There 
was a statistically significant relationship between peripheral smear type 
and TSAT and also between the peripheral smear type and ferritin. Serum 
ferritin level and transferrin saturation was low in microcytic hypochromic 
anemia. 
         Increased bleeding time was present in 3 cases (5.6%). Akisola et al41 
reported increased bleeding time 25.6% in their study. So increased 
bleeding time in some of the patient calls for caution in surgical procedure 
in CKD patients and correction of anemia may improve the bleeding time 
abnormality.  
          In our study 7 cases had neutrophilic leukocytosis, 3 cases had 
lymphocytosis and 6 cases had eosinophilia. No patients had leukaemia or 
lymphoma.  Talwar et al40 found in their study found increased leukocyte 
and eosinophil count in 32% patients. The presence of uremic toxins itself 
can lead to such changes, in addition to the presence of infection. 
   
          A raised ESR in 64.8% patients may be due to presence of low grade 
chronic inflammation and anemia in Chronic Kidney Disease. Afshar et 
al38 found elevated ESR in more than half of patients in their study. 
       There has long been a great interest in iron tests and iron status in 
hemodialysis patients42, 43. In contrast, far less is known regarding iron 
status of patients with nondialysis Chronic Kidney Disease.  It should be 
noted that our results are most applicable to patients with estimated GFR 
<60 ml/min in which CKD is most likely to be present. Hsu et al.30 studied 
iron status in CKD in the NHANES III survey (1988 to 1994) and found 
iron indices suggestive of iron deficiency to be present and to contribute to 
anemia  in many subjects. Typical markers of iron deficiency used in CKD 
are serum ferritin < 100 ng/ml and TSAT < 20%. Clinicians often use these 
thresholds to base iron treatment decisions, and NKF-K/DOQI guidelines 
recommend these levels in nondialysis CKD 3. Specifically, the NKF-
K/DOQI guidelines indicate that if either of the above value is low then 
iron treatment is recommended.  
         Steven fishbane et al31 primary finding was that between 57.8 and 
72.8% of subjects with CKD have either serum ferritin <100 ng/ml or 
TSAT <20%. In contrast to these relatively high values of serum ferritin 
(100 ng/ml) and TSAT (20%) that indicate insufficient iron in CKD, in the 
   
general population lower thresholds of serum ferritin (15 to 30 ng/ml) and 
TSAT (15%) are often used. 
         In our study TSAT <20% in 24 cases (44.4%) and serum ferritin 
<100 ng/ml in 21 cases (38.9%) was present. According to NKF-K/DOQI 
Guidelines8   up to 44.4% of patients in our study are in iron deficient state. 
         In hemodialysis, repeated blood loss makes iron deficiency an almost 
universal problem (Van wyck et al) 42. In contrast, in nondialysis CKD, 
dialysis-related blood loss does not occur, so iron deficiency could occur 
less frequently. The great prevalence of low iron indices found may not 
indicate iron deficiency per se, but rather impaired iron delivery concurrent 
with inflammation, a complex syndrome that occurs with progressive 
CKD. However, it is plausible that iron deficiency might be more common 
than expected because in CKD, the prevalence of gastrointestinal 
pathology with blood loss is probably increased19, sampling of blood for 
laboratory testing is common, and hospitalizations and surgery for other 
intercurrent illness could contribute to blood loss. In addition, many 
patients are treated with Erythropoeisis Stimulating Agents, further 
depleting iron stores. 
           Evidence in support of the high prevalence of iron deficiency that 
found in CKD is provided by a publication by Gotloib et al32. These 
investigators performed sternal bone marrow biopsies on 47 patients with 
   
CKD and Hb < 12 g/dl. Remarkably, severe iron deficiency was found in 
46 of 47 subjects, and these patients were subsequently treated with 
intravenous iron, with most responding with improved Hb concentration32. 
         In our study mean serum ferritin was 278.3 ng/ml and 9cases 
(16.67%) had serum ferritin level >500ng/ml .   
          Hypothetically, higher amounts of ferritin may trap more body iron 
and protect the individual against worsening infection, the start of which 
invariably is associated with inflammation. Hence, inflammation-induced 
hyperferritinemia may result in a so-called “functional iron deficiency,” 
which may be useful in “acute” inflammation by iron containment in the 
RES sites but harmful under “chronic” inflammation by leading to 
refractory anemia such as in CKD or other chronic disease states27.    
           Chronic inflammation is common in patients with CKD, and up to 
40 to 70% of patients with CKD may have increased C-reactive protein 
(CRP) levels on a chronic basis. Hence inflammation probably is the most 
common confounder in CKD-associated hyperferritinemia and may 
contribute to it more strongly than Iron 44 (Jairam et al) 
          Hence, a low ferritin level (e.g., 200 ng/ml in hemodialysis patients 
or 100ng/ml in nondialyzed patients with CKD) is a reliable indicator of 
iron deficiency, whereas a normal to moderately high serum ferritin does 
   
not rule out iron deficiency or indicate adequate or too much Fe on 
board27.   
         It is well known that occult inflammation is commonly present in 
CKD and may increase in prevalence with progressive disease. 
Inflammation has a profound effect on iron indices. Previously, in 
hemodialysis, CRP, an indicator of inflammation, was found to be highly 
correlated with serum ferritin values. Anemia in chronic kidney disease is a 
complex process that reflects an interaction of the erythropoietic processes 
of bone marrow with iron availability and inflammation.45, 46 (Landray MJ 
et al) 
       In our study we have not done variables measuring the inflammatory 
state to allow for more effect of inflammation on serum ferritin.  
        Serum ferritin value was measured in our patients and healthy 
controls and found to exist a significant difference between them.  (P value 
0.047).  There existed no relationship between Glomerular filtration rate 
and serum ferritin. As expected those patients with microcytic 
hypochromic anemia had lower serum ferritin and low transferrin 
saturation (TSAT) when compared to the normocytic normochromic 
anemia 
   
         This clearly indicates that iron deficiency anemia is a one of the 
major component in the anemia of chronic kidney disease due to various 
reasons discussed earlier. 
          So every effort should be done to identify the cause of anemia in 
chronic kidney disease patients and treat the coexistent iron deficiency 
anemia in chronic kidney disease patients and other haematological 
parameters should be monitored to find out coexisting abnormality.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
LIMITATIONS OF THE STUDY 
 
 
      As the study population was small, larger studies are required to 
validate the results of this study. Iron deficiency in CKD should be 
assessed by using other newer methods which include soluble transferrin 
receptors, zinc protoporphyrin, percentage of hypochromic cells, 
reticulocyte hemoglobin concentration and the gold standard method, the 
bone marrow examination for stainable iron. Hepcidin level was not done. 
Also in our patients the probable causes of iron deficiency like occult 
Gastro intestinal blood loss were not excluded by upper gastrointestinal 
endoscopy. Folic acid and vitamin B12 assays are not done. 
          As this was a cross-sectional study, we could not document if the 
findings were persistent. Finally, this study only shows an association, and 
cannot prove the causality. Interventional studies will be needed to finally 
nail down a cause-and-effect relationship. 
 
 
 
 
 
   
CONCLUSION 
1. In our study, we have found that chronic kidney disease affects 
predominantly middle aged population. 
2. All the patients in this study were in the stage 3, 4 or 5 of Chronic 
Kidney Disease (CKD).  
3. Profound anemia was universal in our patients, which is an 
important contributor to the high mortality and morbidity in 
patients with End Stage Renal Disease (ESRD).  
4. There was a significant reduction in Hemoglobin, and Packed Cell 
Volume with progressive increase in severity of CKD stage. 
5. Bleeding time increased in 5.6% patients and elevated Erythrocyte 
Sedimentation Rate was present in more than half of patients. 
6. Normocytic normochromic anemia was found in 70.4 % of the 
patients and microcytic hypochromic anemia in another 20.4%, 
and 9.2% had both type of morphology in the peripheral smear 
picture.  
7. Patients with microcytic hypochromic anemia had relatively low 
serum ferritin and low transferrin saturation (TSAT) when 
compared to the normocytic normochromic anemia patients. 
8. Applying the NKF-K/DOQI  guidelines for nondialysis chronic 
kidney disease  to our population it was found that nearly 38.9% of 
   
the study population did not have target serum ferritin of 100 
ng/ml and 44.4% of study population did not have target TSAT of 
>20%.  So it is vital to address this issue of iron deficiency in 
patients with chronic kidney disease so that necessary 
investigations can be undertaken to find the cause of iron 
deficiency if any.  
9. Adequate supplementation of iron should be given either as oral or 
parenteral route before initiation of dialysis or erythropoietin 
therapy to attain the goals according NKF guidelines.  
10. So every effort should be done to identify the cause of anemia in 
CKD patients and treat the coexistent iron deficiency anemia in 
chronic kidney disease patients and other haematological 
parameters should be monitored to find out coexisting 
abnormality.  
11. Even though treating the complication of CKD like anemia, will 
reduce the mortality and improve the survival, our ultimate aim 
should be focused on the preventive strategies for CKD. This 
include screening high risk population , control of hypertension , 
DM, limiting the use of nephrotoxic drugs like NSAID’S so that a 
large section of our population escape the burden of this killer 
disease.  
   
SUMMARY 
          This study was undertaken with the aim to assess the 
Haematological profile and Serum Iron indices in nondialysis chronic 
kidney disease patients. It is a cross-sectional study conducted in 
Department of Medicine and Nephrology, Govt Rajaji Hospital. 
           A total of 54 patients were included in our study who satisfied the 
diagnostic criteria of CKD and patients underwent clinical and renal 
parameters, haematological profile and iron status. For comparison of the 
results with the general population adequate number of controls were also 
taken. 
           Haemoglobin, packed cell volume was low with increasing severity 
of chronic kidney disease. Bleeding time increased in 5.6% patients and 
elevated ESR was present in more than half of patients. Anemia was 
universal in our population.  Normocytic normochromic anemia was found 
in 70.4 % of the patients and microcytic hypochromic anemia in another 
20.4%, and 9.2% had both type of peripheral smear picture.  Applying the 
NKF-K/DOQI  guidelines for nondialysis chronic kidney disease  to our 
population it was found that nearly 38.9% of the study population did not 
have target serum ferritin of 100 ng/ml and 44.4% of study population did 
not have target TSAT of >20%.  So it is vital to address this issue of iron 
   
deficiency in patients with chronic kidney disease so that necessary 
investigations can be undertaken to find the cause of iron deficiency if any. 
         So every effort should be done to identify the cause of anemia in 
CKD patients and treat the coexistent iron deficiency anemia in chronic 
kidney disease patients. And other haematological parameters should be 
monitored to find out coexisting abnormality. 
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PROFORMA 
 
S. NO   :                      O.P/I.P. NO 
NAME  :           AGE/SEX:  
OCCUPATION : 
ADDRESS  : 
 
CHIEF COMPLAINTS: 
 
DURATION OF ILLNESS:  
  
H/O Bleeding manifestation 
 
PAST HISTORY:      
DM / HT 
 
PERSONAL HISTORY: 
Smoking      Alcoholism Veg/ Nonveg: 
 
FAMILY HISTORY: 
 
GENERAL EXAMINATION: 
 
VITALS:  
PULSE:  BP:  HEIGHT: 
 WEIGHT:    
 
SYSTEMIC EXAMINATION: 
 
CVS  :  
RS  : 
ABDOMEN : 
CNS  : 
 
   
INVESTIGATIONS: 
 
Blood sugar :   Urea : 
 
Serum Creatinine:   Na+  :   K+: 
 
GFR  : 
 
COMPLETE HAEMOGRAM: 
 
Hb :  TC:    DC:  P-     L-     E-      M-    
RBC :  PLATELET:  PCV: 
MCV :  MCHC:             MCH: 
RDW         ESR:    BT:   CT: 
 
PERIPHERAL SMEAR : 
 
SERUM IRON INDICES: 
 
SERUM IRON   : 
FERRITIN   : 
SERUM IRON BINDING CAPACITY: 
TRANSFERRIN SATURATION % : 
ECG 
USG Abdomen:  
Others: 
23Motion occult blood                    Motion ova cyst 
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1  Amaldoss  50  M  5months   N  N  N  N  N  P  62  68  2.5  31  3  9.8 3.3  28.8  4.38 87.3  29.7  34 
2  Immanuvel  59  M  9months  P  P  N  N  N  P  66  92  3  24.75  4  9.1 3.05  29.3  4.09 84.2  31.2  35.4 
3  Kandasamy  50  M  6months  N  P  N  N  N  P  62  54  3  25.833 4  9.4 3.66  31.2  3.84 85.2  26.6  32.1 
4  Arumugam  28  M  14months  N  P  N  N  N  P  55  179 16.6  5.1539 5  5.6 1.75  16.5  4.66 93.1  32  33.9 
5  Suseela  40  F  12months  P  P  N  N  N  P  60  78  3.7  19.14  4  8.8 3.29  28.2  3.89 85.7  26.7  31.2 
6  Palanisamy  42  M  10months  N  N  P  N  N  P  58  352 22.9  3.4474 5  6.4 2.28  21.1  4.14 92.5  28.1  30.3 
7  Nagarajan  27  M  9months  N  P  N  N  N  P  45  210 8.8  8.0256 5  7.3 3.03  25.6  3.16 84.5  24.1  28.5 
8  Chikkaiyappan  43  M  18months  P  P  N  N  N  P  65  149 5.6  15.637 4  5.4 2  18  3.97 74.9  14.4  19.3 
9  Mookaiyan  31  M  4months  N  P  N  N  N  P  42  392 12.7  5.0066 5  5.9 4.15  26.8  3.09 82.9  25.2  28.1 
10  Palaniyammal  37  F  6months  N  N  N  N  N  P  45  58  2.9  19.12  4  8.2 3.12  27.2  2.75 82.9  26.2  30 
11  Vayakattusamy  25  M  11months  N  P  P  N  N  P  48  183 19.6  3.9116 5  3.5 1.89  15.4  2.63 0.43  18.5  22.7 
12  Bakiyaraj  29  M  8months  N  P  N  N  N  P  58  111 4.7  19.025 4  8.1 2.85  23.7  3.3  83.2  28.4  34.2 
13  Tamilarasan  42  M  7months  N  N  N  N  N  P  66  53  3.2  28.073 4  9.4 3.43  29.2  2.6  85.1  27.4  32.2 
14  Samidurai  60  M  9months  N  P  N  N  N  P  57  94  5.6  11.31  5  8.1 3.05  24  2.2  83  30.6  35.8 
15  Balasubramaniyan  37  M  5months   N  N  N  N  N  P  65  76  2.8  33.209 3  10  4.15  36.6  3.78 88.2  25.1  28.1 
16  Velayutham  53  M  10months  P  P  N  N  N  P  67  104 4  20.24  4  8.6 2.58  23.5  2.7  91.1  33.3  36.6 
17  Periyasamy  60  M  8months  N  N  N  N  N  P  65  94  5.6  12.897 5  7.7 4.74  30.4  3.5  64.1  16.2  25.3 
18  Mahalingam  50  M  6months  P  P  N  N  N  P  69  102 5.3  16.274 4  8.3 3.37  28.5  2.5  84.6  24.6  29.1 
19  Veeranan  55  M  5months   P  P  N  N  N  P  63  58  3.5  21.25  4  11  3.41  29.2  2.2  85.6  28.7  33.6 
20  Karuppaiya  59  M  12months  N  P  N  N  N  P  54  140 11.1  5.473  5  4.8 4.65  26.6  2.41 83  29.4  32.8 
21  Murugesan  45  M  15months  P  N  N  N  N  P  46  109 7.9  7.6828 5  7.2 2.52  21.1  3.18 83.7  28.6  34.1 
22  Paramasivam  57  M  6months  N  N  N  N  N  P  70  168 11.6  6.9564 5  7.3 3.42  23.7  2.5  86.3  27.1  30.7 
23  Ramayee  20  F  3months  N  P  N  N  N  P  43  78  3.3  18.45  5  9.8 3.04  28.9  3.72 95  32.2  33.9 
24  Karuppusamy  40  M  9months  N  P  N  P  N  P  60  99  14.4  5.787  5  6  3  19.4  2.98 65  20  30.9 
   
25  Marimuthu  58  M  12months  P  P  N  N  N  P  70  227 11.3  7.0551 5  7.7 2.83  23.6  2.62 83.4  27.2  32.6 
26  Lakshmanan  21  M  8months  N  N  N  N  N  P  36  127 8  7.4375 5  7.5 2.89  25  2.4  86.5  26  30 
27  Meenakshi  28  F  15months  N  P  N  N  N  P  48  112 6.4  9.92  5  8.2 3.19  26.9  4.33 84.3  25.7  30.5 
28  Alagarsamy  49  M  6months  N  N  N  N  N  P  69  78  2.1  41.528 3  7  4.31  26.8  3.34 62.3  16.2  26 
29  Valarmathi  53  F  5months   N  N  N  N  N  P  54  206 7.4  7.49  5  5.7 2.61  21.4  3.22 82  21.8  26.6 
30  Abdul jaffer  44  M  10months  N  P  N  N  P  P  62  140 4.2  19.683 4  8.8 4.22  28.2  3.7  66.8  20.9  31.2 
31  Kowsalyastella  58  F  12months  N  N  N  N  N  P  69  236 8  8.35  5  9.8 3.3  28.8  3.26 87.3  29.7  34 
32  Ochammal  53  F  6months  P  P  N  N  N  P  52  178 5.2  10.27  5  8.7 3.02  25.3  3.7  83.8  28.8  34.4 
33  Janarthanan  49  M  8months  N  N  N  N  N  P  65  192 6.9  11.906 5  9.4 2.94  26  3.67 88.4  33  37.3 
34  Thevendran  38  M  6months  N  N  N  N  N  P  49  216 8  8.6771 5  7.5 3.22  28.3  2.79 87.9  23.3  26.5 
35  Kathamuthu  51  M  12months  N  P  N  N  N  P  57  82  2.5  28.183 4  8.9 2.85  26.3  3.3  92.3  31.2  33.8 
36  Raajeswari  42  F  15months  N  P  N  N  N  P  55  96  3  21.21  4  8.3 2.34  21.9  4.2  93.6  33.5  36 
37  Chinnaiyan  57  M  24months  N  N  N  N  N  P  50  142 3.9  14.779 5  8.2 2.6  22.9  2.97 88.1  31.5  35.8 
38  Janaki  40  F  6months  N  N  N  N  N  P  45  124 3.5  15.18  4  9.3 3.34  30.1  3.2  90.1  27.8  30.9 
39  Subbaiya  55  M  4months  N  N  N  N  N  P  49  76  1.9  30.446 3  9.4 2.69  23.4  2.79 87  31.8  35.7 
40  Patchamuthu  47  M  3months  N  N  N  N  N  P  60  82  2  38.75  3  9.9 3.24  28.7  2.65 88.6  30.6  34.5 
41  Pandiyammal  39  F  6months  N  P  N  N  N  P  51  104 3.5  17.37  4  3.5 1.89  15.4  4.12 81.5  18.5  22.5 
42  Duraisamy  50  M  3months  N  N  N  N  N  P  57  68  2.1  33.929 3  9.6 3.35  28.1  3.47 83.9  28.7  34.2 
43  Abdulla  19  M  6months  N  N  N  N  N  P  30  127 8  6.3021 5  7.7 2.83  23.6  2.75 83.4  27.2  32.6 
44  Muthupandi  57  M  12months  N  N  N  P  N  P  38  156 20.9  2.096  5  4.9 2.96  18  3.11 60  16  27.2 
45  Pandiyan  38  M  8months  N  P  N  N  N  P  49  96  2.1  33.056 3  9  2.8  23.3  2.47 83.2  32.1  38.6 
46  Kumaravelan  23  M  6months  N  N  N  N  N  P  43  189 3.8  18.388 4  8.1 4.08  29.9  3.97 73.3  19.9  27.1 
47  Alagarsamy  44  M  5months   P  N  N  N  N  P  54  67  1.6  45  3  11  3.66  32  2.87 87  30.3  34.7 
48  Ramasamy  52  M  12months  P  P  N  N  N  P  59  98  2.2  32.778 3  8.8 2.92  24.3  3.2  83.2  30.1  36.2 
49  Perikaruppan  57  M  12months  N  N  N  N  N  P  65  107 3  24.977 4  9.4 4.41  30.1  4.1  68.2  21.4  31.4 
50  Kalpana  26  F  4months  N  P  N  N  N  P  42  165 4.2  15.833 4  6  4.31  26.8  4.45 62.3  16.2  26 
51  Ganesan  40  M  6months  N  N  N  N  N  P  60  202 6.7  12.438 5  5.8 2.35  20.6  4.56 87.7  24.7  28.2 
52  Selvaraj  35  M  9months  N  N  N  N  N  P  59  64  1.8  47.801 3  9.8 3.3  28.8  2.18 87.3  29.7  34 
53  Subramani  43  M  12months  N  P  N  N  N  P  62  88  1.9  43.962 3  9.7 4.12  28.9  4.48 70.1  23.5  33.6 
54  Selvi  31  F  3months  N  N  N  N  N  P  49  148 2.4  30.909 3  6.3 3.54  24.9  3.79 69.7  20.7  29.7 
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1  14.6  14  nl  nl  9600  66  30  3  1  nn  N  79  286  27.62 148 
2  14  30  nl  nl  7100  64  23  6  7  nn  N  72  356  20.22 96.2 
3  13.6  12  nl  nl  8100  55  39  4  2  nn  N  44  356  12.35 59.9 
4  13.5  70  nl  nl  8200  58  39  2  1  nn  P  12  219  5.48  1245.2
5  12  18  nl  nl  5800  52  45  3     nn  N  39.7  100  39.7  262 
6  14.2  38  INCR nl  7000  58  39  3     nn  P  119.7 188  63.67 586.4 
7  13.8  40  nl  nl  6900  60  38  2     nn  N  197.4 249  79.25 424.9 
8  31.9  44  nl  nl  6100  58  36  2  2  mh  P  43  372  11.56 27 
9  13.8  64  nl  nl  5900  62  37  1     nn  P  133.8 160  83.63 1880 
10  13.7  28  nl  nl  6500  65  30  4  1  nn  N  56  280  20  890 
11  16.3  36  INCR nl  9700  51  43  3  3  both  P  64  380  16.84 63.8 
12  13  60  nl  nl  8100  59  34  4  3  nn  N  102  402  25.37 298 
13  12.9  30  nl  nl  7300  60  32  4  4  nn  N  49  360  13.61 32.1 
14  14.2  36  nl  nl  8300  63  32  3  2  nn  N  126  367  34.33 532.4 
15  14.9  14  nl  nl  9300  54  41  3  2  nn  N  82  322  25.47 435 
16  14.2  34  nl  nl  7300  60  31  8  1  nn  N  96.2  290  33.1  146 
17  24.5  20  nl  nl  5800  65  32  3  2  mh  P  38  381  9.97  24.3 
18  14.6  70  nl  nl  6300  57  40  2     nn  N  134  288  46.53 836.1 
19  14.5  15  nl  nl  7000  42  49  4  5  nn  N  51.3  270  18.89 146.3 
20  13.8  45  nl  nl  7000  54  40  3  3  nn  P  58  336  17.26 38.5 
21  14.2  20  nl  nl  7400  67  30  3     nn  P  47  361  13.1  279.4 
22  14.1  25  nl  nl  6400  64  30  2  4  nn  P  33  135  24.44 307 
23  13.2  46  nl  nl  7300  62  32  3  3  nn  N  54  299  18.06 243 
24  16.6  70  nl  nl  6000  76  20  3  1  mh  P  43  359  11.97 42.7 
   
25  14.4  30  nl  nl  7100  60  36  4     nn  N  62  192  32.29 187.2 
26  12.9  15  nl  nl  7500  67  30  3     nn  P  76.3  234  32.4  204.7 
27  13.6  18  nl  nl  8100  62  32  2  2  nn  N  88  302  29.14 193.6 
28  22.6  36  nl  nl  8800  40  53  4  3  mh  P  40  392  10.2  27.5 
29  19.9  19  nl  nl  6700  65  32  4  1  both  P  49  334  14.67 33.9 
30  19.3  15  nl  nl  5800  67  30  3     mh  N  53  390  13.59 19.2 
31  14.4  20  nl  nl  6900  62  34  3  1  nn  N  92.7  210  44.14 508.2 
32  13.7  18  nl  nl  4800  61  31  8     nn  P  88  218  40.37 322 
33  13.5  20  nl  nl  5300  57  40  3     nn  N  101  305  33.11 664.8 
34  16.2  14  nl  nl  6400  63  32  2  3  both  P  45  367  12.26 38.2 
35  14.2  14  nl  nl  7900  64  29  3  4  nn  N  70.2  206  33.98 232.9 
36  13.8  22  nl  nl  7100  55  39  4  2  nn  N  86  189  45.5  164 
37  14.2  8  nl  nl  8200  51  44  3  2  nn  N  68  187  36.36 421 
38  14.4  20  nl  nl  6900  64  33  3  2  nn  N  89  204  43.62 258.7 
39  12.7  10  nl  nl  6100  60  36  3  1  nn  N  92  221  41.62 453.6 
40  13  14  nl  nl  5800  52  38  6  4  nn  N  67  176  38.07 397.2 
41  18.7  18  nl  nl  7800  59  35  5  1  both  P  43.1  348  12.35 18.5 
42  12.5  12  nl  nl  6400  72  26  2     nn  N  65  168  38.69 327.5 
43  13.4  36  nl  nl  5000  58  35  5  2  nn  P  46  297  15.49 658.9 
44  14.1  40  INCR nl  7200  56  39  4  1  mh  N  39  339  11.5  24.2 
45  13.9  12  nl  nl  7100  58  40  1  1  nn  N  61.2  210  29.08 244 
46  26.9  34  nl  nl  9600  59  35  5  1  mh  N  40  335  11.94 9.7 
47  16.5  10  nl  nl  8000  66  29  1  4  both  N  49  322  15.21 64.7 
48  14.3  14  nl  nl  5700  57  35  3  5  nn  P  72.7  309  23.03 128.3 
49  18.8  12  nl  nl  7100  71  18  8  3  mh  N  53  375  14.13 19.4 
50  22.6  20  nl  nl  5200  64  32  1  3  mh  P  39  289  13.49 57.8 
51  13  26  nl  nl  5900  75  17  5  3  nn  P  84  269  31.23 164.1 
52  13.6  10  nl  nl  6700  67  26  5  2  nn  P  66  280  23.57 98.4 
53  25.8  14  nl  nl  9300  63  33  1  3  mh  N  59  349  16.9  27.8 
54  26.7  18  nl  nl  4700  62  33  2  3  mh  P  52  388  13.4  12.8 
   
KEY TO MASTER CHART 
Sex    - M  - Male   F   -  Female 
ILL.DURATION - Illness duration 
DM   -  Diabetes mellitus  
HT   -  Hypertension 
H/O BL  -  History of bleeding 
M.OC.BL  -  Motion for occult blood test 
ANE   -  Anemia   WT -   Weight 
CREAT  -  Creatinine 
GFR   -  Glomerular Filtration Rate 
HB   -  Hemoglobin 
PCV   - Packed cell volume   
PLT   -  Platelet 
MCV   - Mean corpuscular volume;  
MCH   -  Mean corpuscular hemoglobin 
MCHC  - Mean corpuscular haemoglobin concentration 
RDW   -  Red cell distribution width 
ESR   -  Erythrocyte sedimentation rate 
BT   -  Bleeding time    
CT   - Clotting time 
WBC   -  White cell count 
N   - Neutrophil;  
L   - Lymphocyte 
E   -  Eosinophil 
M   - Monocyte 
P.S   -  Peripheral smear 
LVH   - Left ventricular hypertrophy 
%TSAT  - % Transferrin saturation  
 
   
 
 
 
 
 
